Navigation Links
Anadys Pharmaceuticals to Present at Bio Investor Forum
Date:10/27/2008

uch forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 and ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2007 and Anadys' Form 10-Q for the quarter ended September 30, 2008. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
2. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
3. Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008
4. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
5. Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
6. ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008
7. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
8. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
9. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
10. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
11. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Vivakor Announces New Acquisition Strategy 2Millstone Medical Outsourcing Appoints New Leadership of Memphis Facility 2Indiana Blood Center Taps tw telecom for Data, Internet and IP Telephony Services 2PSI Commits to Expanding HIV Prevention at Clinton Global Initiative 58120 1PSI Commits to Expanding HIV Prevention at Clinton Global Initiative 58120 2PSI Commits to Expanding HIV Prevention at Clinton Global Initiative 58120 3Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 1Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 2Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 3Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 4Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 5Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression Free Survival in Patients With Advanced Breast Cancer in P 58118 6Sorafenib significantly improves the length of time before breast cancer worsens 58117 1Sorafenib significantly improves the length of time before breast cancer worsens 58117 2